Saturday 17 October 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00. In the quarter to June 2026, EPS fell 17.9%, free cash flow fell 3.25% and total debt fell 52.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.09
0.09
+2.25%
Follow EXOZ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
4.53 | 2.51 | 1.32 | 3.81 |
Net Debt/EBITDA |
2.04 | 1.13 | 0.60 | 1.94 | |
Debt/Assets |
0.99% | 1.08% | 1.31% | 0.51% | |
Debt/Equity |
0.01 | 0.02 | 0.03 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.74 | 0.64 | 0.57 | |
Capex/Depreciation |
(0.23) | (1.23) | (0.93) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.22) | (0.24) | (0.19) | (0.19) | |
Cash per Share |
0.61 | 0.36 | 0.17 | 0.65 | |
Shareholders Equity per Share |
0.64 | 0.41 | 0.18 | 0.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.64 | 0.41 | 0.18 | 0.42 | |
Free Cash Flow |
(1.87) | (2.05) | (1.58) | (1.64) | |
Working Capital |
4.37 | 2.37 | 0.51 | 4.55 | |
Capital Expenditures |
(0.01) | (0.07) | (0.06) | 0.00 | |
Net Current Asset Value |
3.26 | 1.37 | (0.40) | 1.84 | |
| Other line items | |||||
Quick Ratio |
4.36 | 2.27 | 1.10 | 3.62 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.24) | (0.18) | (0.19) | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Average Receivables |
0.43 | 0.63 | 0.45 | 0.23 | |
Average Payables |
0.91 | 1.08 | 1.15 | 1.10 | |
Average Assets |
5.64 | 9.50 | 7.77 | 8.83 | |
Average Common Equity |
0.89 | 6.91 | 5.20 | 5.44 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates